| abstract |
The present invention relates to chemically modified sulfated glycosaminoglycan derivatives selected from the group of heparin, heparan sulfate, dermatan sulfate and chondroitin sulphate with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the derivatives and their medical uses, including treatment of malaria and treatment of vaso-occlusive crisis in sickle cell disease. |